Oak Thistle LLC Sells 493 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Oak Thistle LLC lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 25.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,471 shares of the medical instruments supplier’s stock after selling 493 shares during the period. Oak Thistle LLC’s holdings in West Pharmaceutical Services were worth $518,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of West Pharmaceutical Services by 8.8% during the third quarter. Morgan Stanley now owns 750,306 shares of the medical instruments supplier’s stock valued at $281,524,000 after purchasing an additional 60,927 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its position in West Pharmaceutical Services by 10.8% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,830 shares of the medical instruments supplier’s stock valued at $687,000 after buying an additional 179 shares during the last quarter. Czech National Bank boosted its position in West Pharmaceutical Services by 0.4% in the 4th quarter. Czech National Bank now owns 12,958 shares of the medical instruments supplier’s stock worth $4,563,000 after purchasing an additional 49 shares in the last quarter. Creative Planning boosted its position in West Pharmaceutical Services by 1,287.0% in the 3rd quarter. Creative Planning now owns 44,940 shares of the medical instruments supplier’s stock worth $16,862,000 after purchasing an additional 41,700 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its position in shares of West Pharmaceutical Services by 63.3% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 3,746 shares of the medical instruments supplier’s stock valued at $1,406,000 after buying an additional 1,452 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

WST has been the subject of several recent research reports. UBS Group reduced their price objective on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research note on Friday, February 16th. KeyCorp lifted their price objective on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research note on Tuesday, February 13th. Jefferies Financial Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and lifted their price objective for the company from $323.00 to $536.00 in a research note on Wednesday, February 7th. Finally, StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $435.20.

Check Out Our Latest Analysis on West Pharmaceutical Services

West Pharmaceutical Services Stock Performance

NYSE WST opened at $387.15 on Thursday. The business’s 50-day moving average price is $378.96 and its 200 day moving average price is $363.59. The company has a market capitalization of $28.34 billion, a PE ratio of 49.13, a price-to-earnings-growth ratio of 6.62 and a beta of 1.04. The company has a current ratio of 2.88, a quick ratio of 2.24 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a twelve month low of $310.42 and a twelve month high of $415.73.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last released its quarterly earnings results on Thursday, February 15th. The medical instruments supplier reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.05. West Pharmaceutical Services had a net margin of 20.12% and a return on equity of 21.60%. The business had revenue of $732.00 million during the quarter, compared to analyst estimates of $740.43 million. During the same period last year, the business earned $1.77 EPS. The business’s revenue was up 3.3% on a year-over-year basis. On average, research analysts predict that West Pharmaceutical Services, Inc. will post 7.63 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Wednesday, April 24th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.21%. The ex-dividend date is Tuesday, April 23rd. West Pharmaceutical Services’s dividend payout ratio (DPR) is 10.15%.

Insider Activity

In related news, SVP Silji Abraham sold 7,012 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $365.00, for a total value of $2,559,380.00. Following the completion of the sale, the senior vice president now owns 4,660 shares of the company’s stock, valued at $1,700,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other West Pharmaceutical Services news, SVP Silji Abraham sold 7,012 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $365.00, for a total transaction of $2,559,380.00. Following the sale, the senior vice president now owns 4,660 shares in the company, valued at approximately $1,700,900. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the transaction, the chief accounting officer now directly owns 1,309 shares in the company, valued at approximately $469,695.38. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,978 shares of company stock valued at $26,653,772. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Read More

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.